Replies to post #122216 on Biotech Values

[DewDiligence]

BCRX—They are also developing a HCV nucleoside analog sans the prodrug strategy which I doubt should be taken seriously.

Do you mean they are developing a nucleoside as opposed to a nucleotide—i.e. they are developing something that looks like the first illustration in #msg-42396728? If so, that is indeed a discredited approach.